Navrogen’s Mission

To be an industry leader in the area of humoral immuno oncology (HIO), a process whereby tumors produce factors that suppress the beneficial effects of patient’s immune systems against cancer as well as the therapeutic effects of antibody-based anti-cancer therapies.

We are leveraging our proprietary platform technologies and our unique expertise to build company’s and patient’s value from our pipeline of HIO-refractory therapeutic agents as well as from partnerships with biopharmaceutical companies interested in developing HIO-refractory agents in strategic therapeutic areas.